Daiki Kubomura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Daiki Kubomura has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Yoshiharu Matahira
4 shared publicationsMasanori Yamada
Yaizu Suisankagaku Industry Co., Ltd., Yaizu, Shizuoka 425‑8570, Japan
3 shared publicationsTomoya Ueno
Yaizu Suisankagaku Industry Co., Ltd., Yaizu, Shizuoka 425‑8570, Japan
3 shared publicationsAkira Niijima
2 shared publicationsAyano Masui
Yaizu Suisankagaku Industry Co., Ltd., Shizuoka 425-8570, Japan
2 shared publicationsHideki Matsuda
2 shared publications
Latest Publications
- 28 July 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 14 (4) , 3137-3144
Evaluation of the chondroprotective action of N-acetylglucosamine in a rat experimental osteoarthritis model
It has been demonstrated that oral administration of N-acetylglucosamine (GlcNAc) alleviates the symptoms of osteoarthritis (OA). The aim of the present study was to elucidate the molecular mechanisms for the chondroprotective action of GlcNAc in OA. Biomarkers for type II collagen degradation and synthesis were evaluated, as were histopathological changes, using a rat anterior cruciate ligament transection (ACLT)‑induced OA model. Changes in the expression of genes in the cartilage were assessed via DNA microarray and reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). The results indicated that ACLT induced histopathological changes of articular cartilage, whereas oral administration of GlcNAc (1,000 mg/kg/day for 28 days) significantly suppressed these changes. Additionally, GlcNAc significantly decreased levels of a type II collagen degradation marker in sera compared with that in the ACLT group, although there were no significant changes in the levels of a type II collagen synthesis marker. Furthermore, DNA microarray and reverse transcription‑quantitative polymerase chain reaction results demonstrated that GlcNAc treatment downregulated the expression of periostin, which is likely involved in the degradation of cartilage, whereas GlcNAc upregulated the expression of lipocalin 2, which is involved in the regulation of chondrocyte proliferation and differentiation. In conclusion, the results of the present study suggest that GlcNAc is able to suppress the histopathological changes induced by OA and exhibits a chondroprotective action by inhibiting type II collagen degradation in the articular cartilage, possibly via modulation of the expression of inflammatory and chondroprotective molecules, including periostin and lipocalin 2.
- 28 July 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 14 (4) , 3137-3144
Evaluation of the chondroprotective action of N-acetylglucosamine in a rat experimental osteoarthritis model
It has been demonstrated that oral administration of N-acetylglucosamine (GlcNAc) alleviates the symptoms of osteoarthritis (OA). The aim of the present study was to elucidate the molecular mechanisms for the chondroprotective action of GlcNAc in OA. Biomarkers for type II collagen degradation and synthesis were evaluated, as were histopathological changes, using a rat anterior cruciate ligament transection (ACLT)‑induced OA model. Changes in the expression of genes in the cartilage were assessed via DNA microarray and reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). The results indicated that ACLT induced histopathological changes of articular cartilage, whereas oral administration of GlcNAc (1,000 mg/kg/day for 28 days) significantly suppressed these changes. Additionally, GlcNAc significantly decreased levels of a type II collagen degradation marker in sera compared with that in the ACLT group, although there were no significant changes in the levels of a type II collagen synthesis marker. Furthermore, DNA microarray and reverse transcription‑quantitative polymerase chain reaction results demonstrated that GlcNAc treatment downregulated the expression of periostin, which is likely involved in the degradation of cartilage, whereas GlcNAc upregulated the expression of lipocalin 2, which is involved in the regulation of chondrocyte proliferation and differentiation. In conclusion, the results of the present study suggest that GlcNAc is able to suppress the histopathological changes induced by OA and exhibits a chondroprotective action by inhibiting type II collagen degradation in the articular cartilage, possibly via modulation of the expression of inflammatory and chondroprotective molecules, including periostin and lipocalin 2.
- 21 February 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 13 (4) , 1614-1621
Effect of N-acetylglucosamine administration on cartilage metabolism and safety in healthy subjects without symptoms of arthritis: A case report
N-acetylglucosamine (GlcNAc) is a widely accepted treatment for osteoarthritis (OA); however, its effect on healthy individuals is poorly understood. To evaluate the effect of GlcNAc administration on healthy subjects that do not exhibit symptoms of arthritis, the present randomized, double‑blind, placebo‑controlled study was performed. In the present study, 68 male and female Japanese participants, without symptomatic and radiographic evidence of OA, were enrolled and randomly allocated to receive placebo or GlcNAc (500 or 1,000 mg/day) for 16 weeks. Effects were evaluated using biomarkers for type II collagen degradation and synthesis, collagen type II cleavage (C2C), procollagen type II carboxy-terminal propeptide (PIICP) and their ratio (C2C/PIICP). Furthermore, safety assessments were performed via physical parameters, hematology, blood biochemistry and urinalysis. The results indicated that there was no significant change in the biomarkers for type II collagen degeneration and synthesis during and after the intervention with the placebo and two GlcNAc groups. However, subgroup analysis using subjects with impaired cartilage metabolism (who exhibited enhanced type II collagen degradation and reduced type II collagen synthesis) indicated that the C2C levels were significantly decreased at 8 (P<0.05) and 16 (P<0.01) weeks during the intervention in the two GlcNAc (500 mg and 1,000 mg/day) groups, compared with the placebo group. In contrast, PIICP levels were not notably different in the placebo and two GlcNAc groups. The C2C/PIICP ratio was markedly decreased at 12 and 16 weeks during the intervention in the two GlcNAc groups, compared with the placebo group. Moreover, no supplement‑related adverse events were observed during and after the intervention. In conclusion, these observations indicate that oral administration of GlcNAc at doses of 500 and 1,000 mg/day improves cartilage metabolism in healthy subjects without apparent adverse effects.
- 21 February 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 13 (4) , 1614-1621
Effect of N-acetylglucosamine administration on cartilage metabolism and safety in healthy subjects without symptoms of arthritis: A case report
N-acetylglucosamine (GlcNAc) is a widely accepted treatment for osteoarthritis (OA); however, its effect on healthy individuals is poorly understood. To evaluate the effect of GlcNAc administration on healthy subjects that do not exhibit symptoms of arthritis, the present randomized, double‑blind, placebo‑controlled study was performed. In the present study, 68 male and female Japanese participants, without symptomatic and radiographic evidence of OA, were enrolled and randomly allocated to receive placebo or GlcNAc (500 or 1,000 mg/day) for 16 weeks. Effects were evaluated using biomarkers for type II collagen degradation and synthesis, collagen type II cleavage (C2C), procollagen type II carboxy-terminal propeptide (PIICP) and their ratio (C2C/PIICP). Furthermore, safety assessments were performed via physical parameters, hematology, blood biochemistry and urinalysis. The results indicated that there was no significant change in the biomarkers for type II collagen degeneration and synthesis during and after the intervention with the placebo and two GlcNAc groups. However, subgroup analysis using subjects with impaired cartilage metabolism (who exhibited enhanced type II collagen degradation and reduced type II collagen synthesis) indicated that the C2C levels were significantly decreased at 8 (P<0.05) and 16 (P<0.01) weeks during the intervention in the two GlcNAc (500 mg and 1,000 mg/day) groups, compared with the placebo group. In contrast, PIICP levels were not notably different in the placebo and two GlcNAc groups. The C2C/PIICP ratio was markedly decreased at 12 and 16 weeks during the intervention in the two GlcNAc groups, compared with the placebo group. Moreover, no supplement‑related adverse events were observed during and after the intervention. In conclusion, these observations indicate that oral administration of GlcNAc at doses of 500 and 1,000 mg/day improves cartilage metabolism in healthy subjects without apparent adverse effects.
- 9 June 2016
- Published by Spandidos Publications in Biomedical Reports
- Vol. 5 (2) , 254-258
Tuna extract reduces serum uric acid in gout-free subjects with insignificantly high serum uric acid: A randomized controlled trial
Long-term reduction of serum urate levels is vital in the treatment of gout. However, it is difficult to convince gout-free individuals of the necessity of treatment as few appropriate over-the-counter remedies and dietary supplements are available. Therefore, the present study aimed to investigate the antihyperuricemic efficacy and safety of a tuna extract containing the imidazole compounds to evaluate its potential as a functional food ingredient. A randomized, 4-week, double-blind, placebo-controlled study was conducted. A total of 48 male gout-free subjects with insignificantly high serum uric acid were randomly assigned to low- and high-dose tuna extract groups or a placebo group. The efficacy of the extract was assessed by measuring serum uric acid levels. Furthermore, a safety assessment was performed by physical parameters, hematology, blood biochemistry and urinalysis. The results indicated that the uric acid level was decreased at week 4 during the intervention in the tuna extract groups (low and high dose, −0.23 and −0.34 mg/dl, respectively) compared to the placebo group (−0.07 mg/dl). At week 4 after the intervention, a significant reduction in uric acid levels (−0.41 mg/dl; P<0.05) was observed in the high-dose tuna extract group compared with the placebo group (+0.11 mg/dl). No dose-related adverse events were observed during and following the intervention. Therefore, the present results suggest that oral administration of tuna extract containing the imidazole compounds has hypouricemic activity with no undesirable side effects.
- 9 June 2016
- Published by Spandidos Publications in Biomedical Reports
- Vol. 5 (2) , 254-258
Tuna extract reduces serum uric acid in gout-free subjects with insignificantly high serum uric acid: A randomized controlled trial
Long-term reduction of serum urate levels is vital in the treatment of gout. However, it is difficult to convince gout-free individuals of the necessity of treatment as few appropriate over-the-counter remedies and dietary supplements are available. Therefore, the present study aimed to investigate the antihyperuricemic efficacy and safety of a tuna extract containing the imidazole compounds to evaluate its potential as a functional food ingredient. A randomized, 4-week, double-blind, placebo-controlled study was conducted. A total of 48 male gout-free subjects with insignificantly high serum uric acid were randomly assigned to low- and high-dose tuna extract groups or a placebo group. The efficacy of the extract was assessed by measuring serum uric acid levels. Furthermore, a safety assessment was performed by physical parameters, hematology, blood biochemistry and urinalysis. The results indicated that the uric acid level was decreased at week 4 during the intervention in the tuna extract groups (low and high dose, −0.23 and −0.34 mg/dl, respectively) compared to the placebo group (−0.07 mg/dl). At week 4 after the intervention, a significant reduction in uric acid levels (−0.41 mg/dl; P<0.05) was observed in the high-dose tuna extract group compared with the placebo group (+0.11 mg/dl). No dose-related adverse events were observed during and following the intervention. Therefore, the present results suggest that oral administration of tuna extract containing the imidazole compounds has hypouricemic activity with no undesirable side effects.
- 1 January 2015
- Published by EJournal Publishing in Journal of Life Sciences and Technologies
- Vol. 2 (2)
Oral Intake of N-acetyl-D-glucosamine Suppresses the Growth of Helicobacter Pylori in Gastric Mucosa of Mongolian Gerbils by Increasing Gland Mucus
Journal of Life Sciences and Technologies (JOLST)
- 1 January 2015
- Published by EJournal Publishing in Journal of Life Sciences and Technologies
- Vol. 2 (2)
Oral Intake of N-acetyl-D-glucosamine Suppresses the Growth of Helicobacter Pylori in Gastric Mucosa of Mongolian Gerbils by Increasing Gland Mucus
Journal of Life Sciences and Technologies (JOLST)
- 1 September 2014
- Published by Elsevier in Food Chemistry
- Vol. 159, 328-332
Dose-dependent changes in the levels of free and peptide forms of hydroxyproline in human plasma after collagen hydrolysate ingestion
- 1 September 2014
- Published by Elsevier in Food Chemistry
- Vol. 159, 328-332
Dose-dependent changes in the levels of free and peptide forms of hydroxyproline in human plasma after collagen hydrolysate ingestion
- 1 January 2014
- Published by Japanese Society for Complementary & Alternative Medicine in Japanese Journal of Complementary and Alternative Medicine
- Vol. 11 (2) , 75-80
New Evaluation Method of Muscle Anti-Fatigue Effect
- 1 January 2014
- Published by Japanese Society for Complementary & Alternative Medicine in Japanese Journal of Complementary and Alternative Medicine
- Vol. 11 (2) , 75-80
New Evaluation Method of Muscle Anti-Fatigue Effect
- Open Access
- 1 October 2013
- Published by Functional Food Center in Functional Foods in Health and Disease
- Vol. 3 (10) , 389
Verification of anti-fatigue effect of anserine by angle fatigue indicator based on median frequency changes of electromyograms
Objective: Anserine, which is abundant in avian species and in a wide range of fish such as bonito and tuna, is reported to have anti-fatigue effect. Although chicken soup and bonito soup is traditionally used to recover from physical fatigue, it is generally difficult to verify the effect in humans. This study was to directly demonstrate the anti-fatigue effect of oceanic anserine in humans. Methods: Edible-grade anserine was purified from fish extract with food-grade reagents. Subjects were 17 healthy male volunteers (35.5 ± 5 yr., 75.5 ± 5.0 kg). Each subject performed the isometric exercise tolerance test (ETT) on the rectus femoris muscle twice (Ex_1, Ex_2) both for anserine and water conditions on a different day. Median frequency changes (MDF) during ETTs were calculated and regression curves were calculated over a frequency range of 21-214 Hz. The difference, or angle, between the slopes of Ex_1 and Ex_2 MDF regression curves, which corresponds to the degree of fatigue, was defined as an angle fatigue index and compared between anserine and water intake conditions.Results: MDF decreased during ETTs in most patients and the slopes of regression curves were larger in Ex_2 than in Ex_1. Angle fatigue index for water (control) was significantly larger than that for anserine (p
- 1 October 2013
- Published by Functional Food Center in Functional Foods in Health and Disease
- Vol. 3 (10) , 389
Open AccessVerification of anti-fatigue effect of anserine by angle fatigue indicator based on median frequency changes of electromyograms
Objective: Anserine, which is abundant in avian species and in a wide range of fish such as bonito and tuna, is reported to have anti-fatigue effect. Although chicken soup and bonito soup is traditionally used to recover from physical fatigue, it is generally difficult to verify the effect in humans. This study was to directly demonstrate the anti-fatigue effect of oceanic anserine in humans. Methods: Edible-grade anserine was purified from fish extract with food-grade reagents. Subjects were 17 healthy male volunteers (35.5 ± 5 yr., 75.5 ± 5.0 kg). Each subject performed the isometric exercise tolerance test (ETT) on the rectus femoris muscle twice (Ex_1, Ex_2) both for anserine and water conditions on a different day. Median frequency changes (MDF) during ETTs were calculated and regression curves were calculated over a frequency range of 21-214 Hz. The difference, or angle, between the slopes of Ex_1 and Ex_2 MDF regression curves, which corresponds to the degree of fatigue, was defined as an angle fatigue index and compared between anserine and water intake conditions.Results: MDF decreased during ETTs in most patients and the slopes of regression curves were larger in Ex_2 than in Ex_1. Angle fatigue index for water (control) was significantly larger than that for anserine (p
- 5 April 2011
- Published by Taylor & Francis
- p. 255-260
An Overview on N-Acetylglucosamine and Arthritis
- 1 August 2010
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 13 (4) , 183-188
Effect of anserine ingestion on hyperglycemia and the autonomic nerves in rats and humans
Anserine and L-carnosine are similar dipeptides synthesized by muscles of vertebrates. The functional role of anserine is unknown, although previous studies showed hypoglycemic effects of carnosine through autonomic nerves. Thus, we evaluated the effects of anserine on blood glucose levels and the neural activities. Intraperitoneal administration of specific doses of anserine to hyperglycemic rats reduced hyperglycemia and plasma glucagon concentrations, whereas thioperamide eliminated the effects of anserine. Intraduodenal injection of 0.1 mg anserine to anesthetized rats after laparotomy suppressed sympathetic nerve activity and enhanced activity of the vagal gastric efferent. In addition, oral administration of anserine reduced blood glucose levels during oral glucose tolerance testing in humans. These results suggest the possibility that anserine might be a control factor for the blood glucose, and that histaminergic nerves may be involved in the hypoglycemic effects of anserine.
- 1 August 2010
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 13 (4) , 183-188
Effect of anserine ingestion on hyperglycemia and the autonomic nerves in rats and humans
Anserine and L-carnosine are similar dipeptides synthesized by muscles of vertebrates. The functional role of anserine is unknown, although previous studies showed hypoglycemic effects of carnosine through autonomic nerves. Thus, we evaluated the effects of anserine on blood glucose levels and the neural activities. Intraperitoneal administration of specific doses of anserine to hyperglycemic rats reduced hyperglycemia and plasma glucagon concentrations, whereas thioperamide eliminated the effects of anserine. Intraduodenal injection of 0.1 mg anserine to anesthetized rats after laparotomy suppressed sympathetic nerve activity and enhanced activity of the vagal gastric efferent. In addition, oral administration of anserine reduced blood glucose levels during oral glucose tolerance testing in humans. These results suggest the possibility that anserine might be a control factor for the blood glucose, and that histaminergic nerves may be involved in the hypoglycemic effects of anserine.
- 1 June 2010
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 13 (3) , 123-128
Effect of anserine ingestion on the hyperglycemia and autonomic nerves in rats and humans
Anserine and L-carnosine are similar dipeptides synthesized by muscles of vertebrates. The functional role of anserine is unknown, although previous studies showed hypoglycemic effects of carnosine through autonomic nerves. Thus, we evaluated the effects of anserine on blood glucose levels and neural activities. Intraperitoneal administration of specific doses of anserine to hyperglycemic rats reduced hyperglycemia and plasma glucagon concentrations, whereas thioperamide eliminated the effects of anserine. Intraduodenal injection of 0.1 mg anserine to anesthetized rats after laparotomy suppressed sympathetic nerve activity and enhanced activity of the vagal gastric efferent. In addition, oral administration of anserine reduced blood glucose levels during oral glucose tolerance testing in humans. These results suggest the possibility that anserine might be a control factor for blood glucose, and that histaminergic nerves may be involved in the hypoglycemic effects of anserine.
- 1 June 2010
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 13 (3) , 123-128
Effect of anserine ingestion on the hyperglycemia and autonomic nerves in rats and humans
Anserine and L-carnosine are similar dipeptides synthesized by muscles of vertebrates. The functional role of anserine is unknown, although previous studies showed hypoglycemic effects of carnosine through autonomic nerves. Thus, we evaluated the effects of anserine on blood glucose levels and neural activities. Intraperitoneal administration of specific doses of anserine to hyperglycemic rats reduced hyperglycemia and plasma glucagon concentrations, whereas thioperamide eliminated the effects of anserine. Intraduodenal injection of 0.1 mg anserine to anesthetized rats after laparotomy suppressed sympathetic nerve activity and enhanced activity of the vagal gastric efferent. In addition, oral administration of anserine reduced blood glucose levels during oral glucose tolerance testing in humans. These results suggest the possibility that anserine might be a control factor for blood glucose, and that histaminergic nerves may be involved in the hypoglycemic effects of anserine.